HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab.

Abstract

Characterization of the molecular mechanisms underlying antitumor immune responses and immune escape mechanisms has resulted in the development of more effective immunotherapeutic strategies, including immune checkpoint inhibitor (ICI) therapy. ICIs can induce durable responses in patients with advanced cancer in a wide range of cancer types, however, the majority of the patients fail to respond to this therapy or develop resistance in the course of the treatment. Information about the molecular mechanisms underlying primary and acquired resistance is limited. Although HLA class I molecules are crucial in the recognition of tumor antigens by cytotoxic T lymphocytes, only a few studies have investigated the role of their expression level on malignant cells in ICI resistance. To address this topic, utilizing immunohistochemical staining with monoclonal antibodies (mAbs) we analyzed HLA class I expression level in pre-treatment and post-treatment tumor samples from melanoma patients treated with ipilimumab. Twenty-nine metastases removed from six patients were available for the study, including 18 pre-treatment and 11 post-treatment lesions. Compared to metastases excised before ipilimumab therapy, post-treatment lesions displayed a significantly lower HLA class I expression level on melanoma cells; HLA class I downregulation was most marked in progressing metastases from nonresponding patients. We also evaluated the level of infiltration by CD8+ T cells and NK cells but did not find consistent changes between pre- and post-treatment samples. Our results indicate the potential role of HLA class I downregulation as a mechanism of ICI resistance.

• Authors: Andrea Ladányi, Barbara Hegyi, Tímea Balatoni, Gabriella Liszkay, Raphael Rohregger, Christoph Waldnig, József Dudás, Soldano Ferrone
• Journal: Pathology oncology research : POR (Pathol Oncol Res) Vol. 28 Pg. 1610297 ( 2022) ISSN: 1532-2807 [Electronic] Switzerland
• PMID: 35531074 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Ladányi, Hegyi, Balatoni, Liszkay, Rohregger, Waldnig, Dudás and Ferrone.

Chemical References

• Ipilimumab

Topics

• CD8-Positive T-Lymphocytes
• Down-Regulation
• Humans
• Ipilimumab (therapeutic use)
• Melanoma (pathology)
• Skin Neoplasms (pathology)